多药耐药相关蛋白在乳腺癌组织中的表达

EXPRESSION OF THE MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN (MRP) IN PRIMARY BREAST CARCINOMA

目的 观察多药耐药相关蛋白(MRP)是否在临床乳腺癌组织中表达,了解MRP在乳腺癌多药耐药现象中的临床相关性.方法 用RT-PCR及免疫组化技术检测乳腺癌、乳腺纤维瘤组织中MRP及MRPmRNA的表达.结果 乳腺癌组织的MRP阳性率为56%,乳腺纤维瘤为20%.阳性染色主要位于癌细胞胞浆,胞膜次之.结论 RT-PCR进一步表明术前化疗的乳腺癌组织MRPmRNA表达明显强于乳腺纤维瘤及术前未受化疗者.MRP是乳腺癌化疗时值得重视的因素.

PURPOSEThe present experiments were designed to investigate whether multidrug resistance-associated protein (MRP) could be detected in primary breast carcinoma and realize the clinical relevance of MRP gene expression in the multidrug resistance phenomena in breast cancer. METHODS The expression of MRP was immunohis-tochemically assessed and the expression of MRP mRNA was also detected using RT-PCR in breast carcinoma and fibroadenoma. RESULTS MRP was abundantly expressed in 14 of 25 primary breast carcinoma (56%). In contrast. MRP expression was lower in fibroadenoma (20%). Positive staining of MRP was found primarily in the cy-toplasma and in the plasma membrane of the breast cancer cells. CONCLUSION RT-PCR further showed that the expression of MRP mRNA in surgical specimens from previously chemotherapy-treated patients was significantly stronger than that of the fibroadenoma and untreated. It is thus important to take MRP into account when considering chemotherapy for primary breast carcinoma.